Brief: Cantargia Reports U.S. Regulatory Approval To Start Pancreatic Cancer Phase IIb Trial With Nadunolimab
20/02/2024 15:13
Feb 20 (Reuters) - Cantargia AB CANTA.ST :
* CANTARGIA REPORTS US REGULATORY APPROVAL TO START
PANCREATIC
CANCER PHASE IIB TRIAL WITH NADUNOLIMAB
* TRIAL IS PLANNED TO START MID-2024 WITH INITIAL RESULTS
2025
Source text for Eikon: ID:nMFN2yjzhy
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Cantargia AB
See all newsBrief: Cantargia Publishes Nadunolimab CANFOUR Study Data
Brief: Cantargia Announces Outcome Of Rights Issue, Raising About SEK 75 Mln
Brief: Cantargia Carries Out Rights Issue, Enters Loan Agreement
Brief: Cantargia Q1 Operating Loss Narrows To SEK 36.9 Mln
Brief: Cantargia: Early Results From Phase 1B/2A Nadunolimab Trial In MDS And AML